IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA
September 7, 2011
IN RE: AVANDIA MARKETING, SALES PRACTICES AND PRODUCTS LIABILITY LITIGATION RICHARD V. D'APUZZO ON BEHALF OF HIMSELF AND ALL OTHERS SIMILARLY : SITUATED
SMITHKLINE BEECHAM CORPORATION D/B/A GLAXOSMITHKLINE
The opinion of the court was delivered by: Hon. Cynthia M. Rufe
THIS DOCUMENT APPLIES TO:
MEMORANDUM OPINION AND ORDER
The plaintiff in this case is a former user of the prescription diabetes drug Avandia. Plaintiff does not allege that he has been physically injured as a result of taking Avandia; instead he seeks a refund of any monies he paid for Avandia (including insurance co-pays) and medical monitoring. Each type of relief is sought on behalf of a class of similarly-situated individuals (the "Refund Class" and the "Monitoring Class," respectively), but no classes have been certified. The defendant, GlaxoSmithKline LLC ("GSK"), has filed a motion to dismiss. The motion will be granted.
Plaintiff alleges that GSK promoted the use of Avandia to lower blood-sugar levels of patients with Type 2 diabetes. Plaintiff also alleges that taking Avandia significantly increases the patient's chances of suffering a heart attack or susceptibility to other health risks, and that GSK concealed the risks of Avandia use while promoting the drug's safety, efficacy, and effectiveness through a fraudulent and deceptive marketing program. *fn1 According to Plaintiff, this resulted in Plaintiff and others purchasing Avandia instead of seeking alternative treatments. *fn2
Plaintiff alleges that he is a resident of New Jersey and that on or after May 25, 1999, he was prescribed Avandia for the treatment of Type 2 diabetes, that he purchased the drug and was "exposed" to Avandia for at least 12 weeks, *fn3 and having been exposed, he is at high risk for future myocardial ischemic events. *fn4 These are the only allegations in the complaint specific to Plaintiff.
II. LEGAL STANDARD
Dismissal of a complaint under Federal Rule of Civil Procedure 12(b)(6) for failure to state a claim upon which relief can be granted is appropriate where a plaintiff's "plain statement" does not possess enough substance to show that plaintiff is entitled to relief. *fn5 In determining whether a motion to dismiss is appropriate the court must consider those facts alleged in the complaint, accepting the allegations as true and drawing all logical inferences in favor of the non-moving party. *fn6 Courts are not bound to accept as true legal conclusions couched as factual allegations. *fn7 Something more than a mere possibility of a claim must be alleged; the plaintiff must allege "enough facts to state a claim for relief that is plausible on its face." *fn8 The complaint must set forth direct or inferential allegations with regard to all the material elements necessary to sustain recovery under some viable legal theory. *fn9 The court has no duty to "conjure up unpleaded facts that might turn a frivolous action . . . into a substantial one." *fn10
A. New Jersey Consumer Fraud Act The complaint alleges a
claim on behalf of the proposed Refund and Medical Monitoring Classes
for violations of the New Jersey Consumer Fraud Act ("NJCFA").
*fn11 To state a claim under the NJCFA, a
plaintiff must allege unlawful conduct, an ascertainable loss, and
that the loss was caused by the unlawful conduct. *fn12
The plaintiff is not required to allege reliance or
malicious intent, but the loss must be actual, not hypothetical, and
cannot be based on a fraud-on-the-market theory. *fn13 Plaintiff
alleges that Avandia is more expensive than one alternative treatment,
insulin, but does not allege that he would have been treated with
insulin; nor does the complaint allege that other drugs Plaintiff
identifies as alternatives to Avandia, such as Actos, are less
expensive, or that his physician would have prescribed a
less-expensive treatment regimen. "Due to the discretion of the
prescribing physician, the injury alleged is entirely hypothetical,
and cannot provide the basis for a claim under the NJCFA."*fn14
Plaintiff's claim under the NJCFA on behalf of the proposed Medical Monitoring Class has been rejected by the New Jersey Supreme Court, which held in a similar case involving the drug Vioxx that: plaintiffs do not allege a personal physical injury. Thus, we conclude that because plaintiffs cannot satisfy the definition of harm to state a product liability claim under the [Product Liability Act ("PLA")], plaintiffs' claim for medical monitoring damages must fail. Plaintiffs' effort to expand the definition of harm to include medical monitoring is best directed to the Legislature.
Plaintiffs also seek to avoid the requirements of the PLA by asserting their claims as CFA claims. However, the Legislature expressly provided in the PLA that claims for "harm caused by a product" are governed by the PLA "irrespective of the theory underlying the claim." N.J.S.A. 2A:58C-1(b)(3). We explained in [another case], that "[t]he language chosen by the Legislature in enacting the PLA is both expansive and inclusive, encompassing virtually all possible causes of action in relating to harms caused by consumer and other products." As a result, we declared that "[i]n light of the clear intention of our Legislature to include all [product liability] claims within the scope of the PLA, we find no ground on which to conclude that the claims being raised by plaintiffs, regarding an ordinary household product used by consumers, were excluded from the scope of" the PLA. We reach that same conclusion here. *fn15
Although Plaintiff argues that he has not brought a claim under the PLA (and presumably cannot), he cannot distinguish this case from the holding in Sinclair: regardless of the legal theory, a claim that a product caused any harm can only be asserted under the PLA.
B. Unjust Enrichment
Plaintiff alleges a claim on behalf of the proposed Refund Class
for unjust enrichment. Under New Jersey law, a plaintiff must allege
that the defendant received a benefit from the plaintiff and that
allowing the defendant to keep this benefit would be unjust.
*fn16 There is no separate tort cause of action
for unjust enrichment in New Jersey; instead, unjust enrichment
provides the underlying logic for several torts, and also provides the
basis for establishing quasi-contract liability. *fn17
Here, Plaintiff has not alleged a direct relationship
with GSK which would be necessary to impose quasi-contract liability,
or that GSK refused to provide its product after Plaintiff provided it
with a benefit. *fn18 In the absence of some
sort of contractual relationship, or a separate tort, Plaintiff has
failed to allege a claim for unjust enrichment.
Plaintiff's complaint fails to state any claim upon which relief can be granted. Defendant's motion to dismiss will be granted without prejudice; Plaintiff may file an amended complaint.
An appropriate order will be entered.